• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿毒症患者血液透析和血液滤过后碳水化合物代谢的研究。

Studies of carbohydrate metabolism after hemodialysis and hemofiltration in uremic patients.

作者信息

Geronemus R, Bosch J P, Thornton J, Rayfield E J

出版信息

Arch Intern Med. 1982 Apr;142(4):707-10.

PMID:7041844
Abstract

To assess the effects of dialysis or hemofiltration on carbohydrate metabolism in uremia, we performed intravenous (IV) glucose tolerance tests (IV GTTs) after an overnight fast 48 hours following the last treatment in ten patients with chronic renal failure. Samples were obtained for plasma glucose, insulin, glucagon, and growth hormone levels throughout the GTTs in addition to basal samples for levels of plasma potassium and bicarbonate. The IV GTTs were performed at the end of a four-month period of standard hemodialysis (period 1) and then at the end of a four-month period of hemofiltration (period 2). Patients had mild glucose intolerance that did not change after hemofiltration, although the exaggerated insulin responses to glucose administration did significantly decrease in period 2. The fasting hyperglucagonemia did not decrease after hemofiltration but exhibited normal suppression with IV glucose. Levels of basal plasma bicarbonate and basal plasma potassium did not change significantly in period 2. Further studies investigating the beneficial metabolic effect of hemofiltration would seem to be indicated based on the data reported herein.

摘要

为评估透析或血液滤过对尿毒症患者碳水化合物代谢的影响,我们在十名慢性肾衰竭患者最后一次治疗48小时后的空腹过夜后进行了静脉葡萄糖耐量试验(IV GTT)。除了采集基础样本检测血浆钾和碳酸氢盐水平外,在整个葡萄糖耐量试验期间还采集样本检测血浆葡萄糖、胰岛素、胰高血糖素和生长激素水平。静脉葡萄糖耐量试验在标准血液透析四个月结束时(第1阶段)进行,然后在血液滤过四个月结束时(第2阶段)进行。患者有轻度葡萄糖不耐受,血液滤过后无变化,尽管在第2阶段对葡萄糖给药的过度胰岛素反应显著降低。空腹高胰高血糖素血症在血液滤过后未降低,但静脉注射葡萄糖后表现出正常抑制。第2阶段基础血浆碳酸氢盐和基础血浆钾水平无显著变化。基于本文报道的数据,似乎需要进一步研究以探讨血液滤过有益的代谢作用。

相似文献

1
Studies of carbohydrate metabolism after hemodialysis and hemofiltration in uremic patients.尿毒症患者血液透析和血液滤过后碳水化合物代谢的研究。
Arch Intern Med. 1982 Apr;142(4):707-10.
2
Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.尿毒症和血液透析对胰高血糖素周转及代谢效应的影响。
J Clin Invest. 1976 Mar;57(3):722-31. doi: 10.1172/JCI108330.
3
Hyperglucagonemia of renal failure.肾衰竭时的高胰高血糖素血症。
J Clin Invest. 1974 Mar;53(3):841-7. doi: 10.1172/JCI107624.
4
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
5
Glucose, insulin and glucagon response to intravenous glucose load in patients on chronic hemodialysis.慢性血液透析患者对静脉注射葡萄糖负荷的葡萄糖、胰岛素和胰高血糖素反应。
Isr J Med Sci. 1988 Jan;24(1):15-9.
6
[Insulin resistance in the uremic patient: effects of hemodialysis].
Boll Soc Ital Biol Sper. 1990 Oct;66(10):993-9.
7
[GH, insulin and glucide intolerance in chronic uremia. Changes during hemodialysis treatment and after renal transplantation].[慢性尿毒症中的生长激素、胰岛素与糖耐受不良。血液透析治疗期间及肾移植后的变化]
Minerva Nefrol. 1980 Oct-Dec;27(4):655-8.
8
[Aspects of carbohydrate metabolism in chronic uremic patients treated with periodic hemodialysis].[接受定期血液透析治疗的慢性尿毒症患者的碳水化合物代谢方面]
Minerva Nefrol. 1967 Oct-Dec;14(4):158-62.
9
Abnormalities in the regulation of growth hormone in chronic renal failure.慢性肾衰竭中生长激素调节异常。
Arch Intern Med. 1978 Feb;138(2):267-71.
10
[Radioimmunologic analysis of insulin (IRI) in glucose metabolism in uremic patients].[尿毒症患者糖代谢中胰岛素(IRI)的放射免疫分析]
Riv Eur Sci Med Farmacol. 1989 Aug;11(4):329-39.

引用本文的文献

1
Insulin Resistance in a Hospitalized COVID-19 Patient: A Case Review.一名住院COVID-19患者的胰岛素抵抗:病例回顾
Clin Diabetes. 2021 Apr;39(2):228-232. doi: 10.2337/cd20-0036.